ES2758679T3 - Composiciones que comprenden cepas bacterianas - Google Patents

Composiciones que comprenden cepas bacterianas Download PDF

Info

Publication number
ES2758679T3
ES2758679T3 ES16731641T ES16731641T ES2758679T3 ES 2758679 T3 ES2758679 T3 ES 2758679T3 ES 16731641 T ES16731641 T ES 16731641T ES 16731641 T ES16731641 T ES 16731641T ES 2758679 T3 ES2758679 T3 ES 2758679T3
Authority
ES
Spain
Prior art keywords
composition
asthma
compositions
treatment
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16731641T
Other languages
English (en)
Spanish (es)
Inventor
George Grant
Angela Margaret Patterson
Imke Mulder
Seanin Mccluskey
Emma Raftis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4D Pharma Research Ltd
Original Assignee
4D Pharma Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1510469.8A external-priority patent/GB201510469D0/en
Priority claimed from GBGB1520628.7A external-priority patent/GB201520628D0/en
Priority claimed from GBGB1604566.8A external-priority patent/GB201604566D0/en
Application filed by 4D Pharma Research Ltd filed Critical 4D Pharma Research Ltd
Application granted granted Critical
Publication of ES2758679T3 publication Critical patent/ES2758679T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
ES16731641T 2015-06-15 2016-06-15 Composiciones que comprenden cepas bacterianas Active ES2758679T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1510469.8A GB201510469D0 (en) 2015-06-15 2015-06-15 Compostions comprising bacterial strains
GBGB1520628.7A GB201520628D0 (en) 2015-11-23 2015-11-23 Compositions comprising bacterial strains
GBGB1604566.8A GB201604566D0 (en) 2016-03-17 2016-03-17 Compositions comprising bacterial strains
PCT/GB2016/051773 WO2016203220A1 (en) 2015-06-15 2016-06-15 Compositions comprising bacterial strains

Publications (1)

Publication Number Publication Date
ES2758679T3 true ES2758679T3 (es) 2020-05-06

Family

ID=56194512

Family Applications (3)

Application Number Title Priority Date Filing Date
ES16731641T Active ES2758679T3 (es) 2015-06-15 2016-06-15 Composiciones que comprenden cepas bacterianas
ES18167277T Active ES2863913T3 (es) 2015-06-15 2016-06-15 Composiciones que comprenden cepas bacterianas
ES19170925T Active ES2787523T3 (es) 2015-06-15 2016-06-15 Composiciones que comprenden cepas bacterianas

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES18167277T Active ES2863913T3 (es) 2015-06-15 2016-06-15 Composiciones que comprenden cepas bacterianas
ES19170925T Active ES2787523T3 (es) 2015-06-15 2016-06-15 Composiciones que comprenden cepas bacterianas

Country Status (32)

Country Link
US (4) US10493112B2 (enExample)
EP (4) EP3884953A1 (enExample)
JP (2) JP6389950B2 (enExample)
KR (1) KR20180012845A (enExample)
CN (2) CN108738311B (enExample)
AU (2) AU2016278069B2 (enExample)
BR (1) BR112017025003A2 (enExample)
CA (2) CA3182899A1 (enExample)
CL (1) CL2017003191A1 (enExample)
CO (1) CO2017013231A2 (enExample)
CY (3) CY1122467T1 (enExample)
DK (3) DK3369425T3 (enExample)
EA (1) EA201890049A1 (enExample)
ES (3) ES2758679T3 (enExample)
HR (3) HRP20192057T1 (enExample)
HU (3) HUE052737T2 (enExample)
IL (1) IL255783B2 (enExample)
LT (3) LT3549592T (enExample)
MA (1) MA41060B1 (enExample)
MD (3) MD3549592T2 (enExample)
ME (2) ME03584B (enExample)
MX (1) MX2017016564A (enExample)
PE (1) PE20180266A1 (enExample)
PL (3) PL3204025T3 (enExample)
PT (3) PT3549592T (enExample)
RS (3) RS59558B1 (enExample)
SG (2) SG10201912322PA (enExample)
SI (3) SI3549592T1 (enExample)
SM (3) SMT202000227T1 (enExample)
TW (2) TWI782682B (enExample)
WO (1) WO2016203220A1 (enExample)
ZA (1) ZA201707774B (enExample)

Families Citing this family (46)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactƩriennes
EP3662917A1 (en) 2015-06-15 2020-06-10 4D Pharma Research Limited Compositions comprising bacterial strains
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactƩriennes
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactƩriennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
KR102658297B1 (ko) 2016-06-14 2024-04-18 ė² ė‹Øķƒ€ ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģ‹œģ¦ˆ, ģøķ¬. ķ“ė”œģŠ¤ķŠøė¦¬ė””ģ›€ ė””ķ”¼ģ‹¤ė ˆ ź°ģ—¼ģ˜ ģ¹˜ė£Œ
TWI802545B (zh) 2016-07-13 2023-05-21 č‹±å•†ļ¼”ļ¼¤č£½č—„ęœ‰é™å…¬åø 包含ē“°čŒčŒę Ŗ之ēµ„合ē‰©
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CA3211208A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactƩriennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactƩriennes
GB201806779D0 (en) * 2018-04-25 2018-06-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
TWI767013B (zh) * 2017-06-14 2022-06-11 č‹±å•†4Dč£½č—„ē ”ē©¶ęœ‰é™å…¬åø 包含ē“°čŒå“ē³»ä¹‹ēµ„ęˆē‰©
JP2020523326A (ja) 2017-06-14 2020-08-06 ćƒ•ć‚©ćƒ¼ćƒ‡ć‚£ćƒ¼ ćƒ•ć‚”ćƒ¼ćƒž ćƒŖć‚µćƒ¼ćƒ ćƒŖ惟惆惃惉ļ¼”ļ¼¤ ļ¼°ļ½ˆļ½ļ½’ļ½ļ½ ļ¼²ļ½…ļ½“ļ½…ļ½ļ½’ļ½ƒļ½ˆ ļ¼¬ļ½‰ļ½ļ½‰ļ½”ļ½…ļ½„ ē“°čŒę Ŗć‚’å«ć‚€ēµ„ęˆē‰©
LT3743086T (lt) 2018-05-11 2022-06-10 4D Pharma Research Limited Kompozicijos, apimančios bakterinius kamienus
JP7558170B2 (ja) 2018-08-17 2024-09-30 ćƒ“ć‚§ćƒ€ćƒ³ć‚æ 惐悤ć‚Ŗ悵悤ć‚Øćƒ³ć‚·ćƒ¼ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ č…ø内ęƒē“ ē—‡ć‚’ęø›å°‘ć•ć›ć€å¾®ē”Ÿē‰©å¢ć‚’å¾©å…ƒć™ć‚‹ę–¹ę³•
TWI721549B (zh) * 2018-09-04 2021-03-11 ꘟ聚ę؊ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø ꈈ갏å‰Æꓬę”æ菌ē”Øę–¼ę²»ē™‚ę…¢ę€§č…Žč‡Ÿē–¾ē—…之ē”Ø途
TWI688394B (zh) * 2018-09-04 2020-03-21 ꘟ聚ę؊ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø ꈈ갏å‰Æꓬę”æ菌ē”Øę–¼é é˜²ęˆ–ę²»ē™‚ę…¢ę€§é˜»å”žę€§č‚ŗē—…之ē”Ø途
CN110917219B (zh) * 2018-09-04 2021-09-07 ꘟ聚ę؊ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø ꈈ갏å‰ÆꋟꝆ菌ē”ØäŗŽåˆ¶å¤‡é¢„防和/ęˆ–ę²»ē–—ę…¢ę€§é˜»å”žę€§č‚ŗē—…ēš„医čÆē»„ęˆē‰©ēš„ē”Ø途
US12629395B2 (en) 2018-09-10 2026-05-19 Riken Composition for inhibiting trypsin activity containing as active ingredient bacterium belonging to genus Paraprevotella
CA3112501A1 (en) * 2018-09-10 2020-03-19 Riken Composition for inhibiting trypsin activity containing as active ingredient bacterium belonging to genus paraprevotella
WO2020055193A1 (en) * 2018-09-14 2020-03-19 Industry-Academic Cooperation Foundation, Yonsei University Microorganism with antibacterial activity for enteric pathogenic bacteria and pharmaceutical composition for preventing and treating enteric pathogenic bacteria induced disease using the same
WO2020069282A1 (en) * 2018-09-27 2020-04-02 Research Development Foundation Methods and probiotic compositions for the treatment of bone disorders
US11116803B2 (en) * 2018-10-31 2021-09-14 Multistars Biotechnology Company Limited Method of treating lung cancer using Parabacteroides goldsteinii
TW202034949A (zh) * 2018-11-02 2020-10-01 č‹±å•†4Dč£½č—„ē ”ē©¶ęœ‰é™å…¬åø 包含ē“°čŒčŒę Ŗ之ēµ„ęˆē‰©
AU2019396657A1 (en) 2018-12-12 2021-07-08 4D Pharma Research Limited Compositions comprising Parabacteroides bacterial strains for treating cancer
CN110172427A (zh) * 2019-06-11 2019-08-27 ę±Ÿå—å¤§å­¦ äø€ē§ęé«˜ē‹„갏å‰Æę‹Ÿę†čŒå†»å¹²å­˜ę“»ēŽ‡ēš„ę–¹ę³•åŠåŗ”ē”Ø
JP7761556B2 (ja) * 2019-09-18 2025-10-28 ćƒŖć‚µćƒ¼ćƒ ćƒ‡ć‚£ćƒ™ćƒ­ćƒƒćƒ—ćƒ”ćƒ³ćƒˆ ćƒ•ć‚”ć‚¦ćƒ³ćƒ‡ćƒ¼ć‚·ćƒ§ćƒ³ ä»£č¬ę€§ē–¾ę‚£ćŠć‚ˆć³éšœå®³ć‚’ę²»ē™‚ć™ć‚‹ćŸć‚ć®ę–¹ę³•ćŠć‚ˆć³ćƒ—ćƒ­ćƒć‚¤ć‚Ŗćƒ†ć‚£ćƒƒć‚Æēµ„ęˆē‰©
WO2021221110A1 (ja) * 2020-04-29 2021-11-04 å­¦ę ”ę³•äŗŗꅶꇉē¾©å”¾ ļ¼“ļ½ˆļ¼‘ē“°čƒžåŠć³ļ¼åˆćÆļ¼“ļ½ˆļ¼‘ļ¼—ē“°čƒžć®å¢—ę®–åˆćÆę“»ę€§åŒ–ć‚’čŖ˜å°Žć™ć‚‹å°č…ø内ē“°čŒ
CN112410242A (zh) * 2020-08-25 2021-02-26 äøŠęµ·åø‚ē¬¬åäŗŗę°‘åŒ»é™¢ äø€ę Ŗ分ē¦»č‡Ŗē›“肠ē™Œč‚æē˜¤ē»„ē»‡ēš„ē‹„갏å‰ÆꋟꝆ菌ę Ŗ及其åŗ”ē”Ø
EP3967314A1 (en) * 2020-09-15 2022-03-16 Institut national de recherche pour l'agriculture l'alimentation et l'environnement Parabacteroides distasonis strains for use thereof in the treatment and prevention of gastrointestinal diseases and of disorders associated with gastrointestinal diseases
CN114908022A (zh) * 2022-06-17 2022-08-16 äø­å›½ęµ·ę“‹å¤§å­¦ äø€ē§å‰Æę‹Ÿę†čŒå±žčŒę ŖåŠå…¶åŸ¹å…»ę–¹ę³•å’Œåŗ”ē”Ø
AU2024327567A1 (en) * 2023-08-22 2026-01-08 Danisco Usa Inc. Methods and compositions for immune system regulation
CN120041316A (zh) * 2023-11-27 2025-05-27 ꅕꁩļ¼ˆå¹æ州ļ¼‰ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø å‰Æę‹Ÿę†čŒå±žčŒę Ŗć€åŸ¹å…»ē‰©ć€čŒå‰‚及其åŗ”ē”Ø

Family Cites Families (360)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
KR100225087B1 (ko) 1990-03-23 1999-10-15 ķ•œģŠ¤ ė°œķ„°ė¼ė²¤ ķ”¼ķƒ€ģ•„ģ œģ˜ ģ‹ė¬¼ė‚“ ė°œķ˜„
ES2068586T5 (es) 1990-05-09 2004-12-01 Novozymes A/S Una preparacion de celulasa que comprende una enzima endoglucanasa.
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
CA2100919A1 (en) 1992-07-20 1994-01-21 Takaharu Yamamoto Species-specific oligonucleotides for bifidobacteria and a method of detection using the same
WO1994013820A1 (en) 1992-12-10 1994-06-23 Gist-Brocades N.V. Production of heterologous proteins in filamentous fungi
US5741665A (en) 1994-05-10 1998-04-21 University Of Hawaii Light-regulated promoters for production of heterologous proteins in filamentous fungi
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM823094A0 (en) 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
RU2078815C1 (ru) 1995-01-17 1997-05-10 ŠœŠ¾ŃŠŗŠ¾Š²ŃŠŗŠøŠ¹ Š½Š°ŃƒŃ‡Š½Š¾-ŠøссŠ»ŠµŠ“Š¾Š²Š°Ń‚ŠµŠ»ŃŒŃŠŗŠøŠ¹ ŠøŠ½ŃŃ‚Šøтут эŠæŠøŠ“ŠµŠ¼ŠøŠ¾Š»Š¾Š³ŠøŠø Šø Š¼ŠøŠŗрŠ¾Š±ŠøŠ¾Š»Š¾Š³ŠøŠø ŠøŠ¼.Š“.Š.Š“Š°Š±Ń€ŠøчŠµŠ²ŃŠŗŠ¾Š³Š¾ ŠØтŠ°Š¼Š¼ Š±Š°ŠŗтŠµŃ€ŠøŠ¹ bifidobacterium breve, ŠøсŠæŠ¾Š»ŃŒŠ·ŃƒŠµŠ¼Ń‹Š¹ Š“Š»Ń ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя Š±Š°ŠŗтŠµŃ€ŠøŠ¹Š½Ń‹Ń… Š»ŠµŃ‡ŠµŠ±Š½Š¾-ŠæрŠ¾Ń„ŠøŠ»Š°ŠŗтŠøчŠµŃŠŗŠøх Š±ŠøфŠøŠ“Š¾ŃŠ¾Š“ŠµŃ€Š¶Š°Ń‰Šøх ŠæрŠµŠæŠ°Ń€Š°Ń‚Š¾Š²
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk ć‚¤ćƒ³ć‚æćƒ¼ćƒ•ć‚§ćƒ­ćƒ³ē”£ē”Ÿå¢—強剤
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
AUPN698495A0 (en) 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
SE508045C2 (sv) 1996-02-26 1998-08-17 Arla Ekonomisk Foerening Adhesionsinhibitorer, preparat innehƄllande desamma och fƶrfarande fƶr framstƤllning dƤrav
CA2249189A1 (en) 1996-03-20 1997-09-25 The University Of New South Wales Alteration of microbial populations in the gastrointestinal tract
AUPN881396A0 (en) 1996-03-20 1996-04-18 Arnott's Biscuits Limited Enhancement of microbial colonization of the gastrointestinal tract
ATE317005T1 (de) 1996-03-27 2006-02-15 Novozymes As Alkaline-phosphatase-defiziente, filamentƶse pilze
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
WO1998043081A1 (en) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
SE511524C2 (sv) 1997-06-02 1999-10-11 Essum Ab Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning fƶr bekƤmpning av patogena tarmbakterier
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARĪ³ agonists for inhibition of inflammatory cytokine production
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
DE19826928A1 (de) 1998-06-17 1999-12-23 Novartis Consumer Health Gmbh Arzneimittel, lebensfƤhige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7090973B1 (en) 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
WO2001016120A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
CA2395343C (en) 2000-02-08 2009-06-30 F. Hoffmann-La Roche Ag Use of acid-stable proteases in animal feed
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1414853A2 (en) 2000-11-27 2004-05-06 Washington University Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon
DE10101793A1 (de) 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzĆ¼ndlicher Darmerkrankungen
EP1227152A1 (en) 2001-01-30 2002-07-31 SociƩtƩ des Produits NestlƩ S.A. Bacterial strain and genome of bifidobacterium
KR100437497B1 (ko) 2001-03-07 2004-06-25 ģ£¼ģ‹ķšŒģ‚¬ ķ”„ė”œė°”ģ“ģ˜¤ė‹‰ ė”œķƒ€ė°”ģ“ėŸ¬ģŠ¤ ė° ģœ ķ•“ ėÆøģƒė¬¼ ģ–µģ œ ķ™œģ„±ģ„ ź°€ģ§€ėŠ” ģ‹ ź·œė‚“ģ‚°ģ„± ė½ķ† ė°”ģ‹¤ėŸ¬ģŠ¤ ė£Øķ…Œė¦¬ ķ”„ė”œė°”ģ“ģ˜¤-16 ė° ģ“ė„¼ķ•Øģœ ķ•˜ėŠ” ģƒź· ķ™œģ„±ģ œ
EP1243273A1 (en) 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1260227A1 (en) 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
MXPA04001999A (es) 2001-09-05 2004-07-16 Vsl Pharmaceuticals Inc Bacterias de acido lactico que comprende dinucleotidos de citosina-guanina no metilados para usarse en terapia.
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
WO2003045317A2 (en) 2001-11-27 2003-06-05 Washington University Therapeutic protein and treatments
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
DE10206995B4 (de) 2002-02-19 2014-01-02 Orthomol Pharmazeutische Vertriebs Gmbh MikronƤhrstoffkombinationsprodukt mit Pro- und Prebiotika
JP2003261453A (ja) 2002-03-11 2003-09-16 Nippon Berumu Kk ļ¼„ļ¼Žćƒ•ć‚§ć‚«ćƒŖć‚¹ć‹ć‚‰ćŖ悋ꊗ腫ē˜å‰¤åŠć³ę”¾å°„ē·šé˜²č­·å‰¤
SI1565547T2 (sl) 2002-06-28 2013-02-28 Biosearch S.A. ProbiotiĆ¤Å›ni sevi, postopek za izbiranje le-teh, njihovi sestavki in njihova uporaba
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1481681A1 (en) 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
AU2003247193A1 (en) 2003-07-23 2005-02-04 M.D.Lab Corp. Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus
US7485325B2 (en) 2003-08-06 2009-02-03 Gayle Dorothy Swain Animal food supplement compositions and methods of use
JP4683881B2 (ja) 2003-08-27 2011-05-18 ęœ‰é™ä¼šē¤¾ć‚¢ćƒ¼ć‚Æꊀē ” ꊗ腫ē˜ę“»ę€§å‰¤
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
WO2005030133A2 (en) 2003-09-22 2005-04-07 Yale University Treatment with agonists of toll-like receptors
GB0323039D0 (en) 2003-10-01 2003-11-05 Danisco Method
JP4740866B2 (ja) 2003-10-24 2011-08-03 ćƒŠćƒ ćƒ­ćƒ¼ć‚¼ ćƒ•ć‚§ćƒ³ćƒŽćƒ¼ćƒˆć‚·ćƒ£ćƒƒćƒ— ćƒ‹ćƒ„ćƒ¼ćƒˆćƒŖć‚·ć‚¢ ä¹³å…å‘ć‘ć‚·ćƒ³ćƒć‚¤ć‚Ŗćƒ†ć‚£ćƒƒć‚Æēµ„ęˆē‰©
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20090257993A1 (en) 2003-12-17 2009-10-15 M Rabet Laura Lactic Acid Producing Bacteria and Lung Function
ES2235642B2 (es) 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
CA2557800A1 (en) 2004-03-22 2005-10-06 Yossef Raviv Cellular and viral inactivation
WO2005107381A2 (en) 2004-05-07 2005-11-17 Hans-Gustaf Ljunggren Use of flagellin as an adjuvant for vaccine
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
CN101022826A (zh) 2004-06-07 2007-08-22 哈ē½—å°”Ā·ęˆ“ē»“Ā·č“” ē”ØäŗŽē™Œē—‡ę²»ē–—ēš„ē»†čŒē»„合ē‰©
DK1629850T4 (da) 2004-08-24 2013-07-01 Nutricia Nv NƦringssammensƦtning indeholdende ufordĆøjelige oligosaccharider
US20060062774A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for maintaining and restoring normal urogenital flora
KR100468522B1 (ko) 2004-10-12 2005-01-31 ģ£¼ģ‹ķšŒģ‚¬ ķ”„ė”œė°”ģ“ģ˜¤ė‹‰ ģ½”ė”œė‚˜ė°”ģ“ėŸ¬ģŠ¤ģ™€ ė¼ģ§€ ģØģ½”ė°”ģ“ėŸ¬ģŠ¤ 2ķ˜•ģ˜ ģƒģœ”ģ„ ģ–µģ œķ•˜ėŠ” ģ‹ ź·œķ•œ ė‚“ģ‚°ģ„± ķ”„ė”œė°”ģ“ģ˜¤ķ‹± ģ—”ķ…Œė”œģ½”ģ»¤ģŠ¤ķ›¼ģ‹œģ›€ ķ”„ė”œė°”ģ“ģ˜¤-63
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
PL2805625T5 (pl) 2005-02-28 2023-03-13 N.V. Nutricia Kompozycja odżywcza z prebiotykami i probiotykami
US20100048595A1 (en) 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
US20090233888A1 (en) 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
JP2006265212A (ja) 2005-03-25 2006-10-05 Institute Of Physical & Chemical Research ļ¼©ļ½Œāˆ’ļ¼’ļ¼‘ē”£ē”ŸčŖ˜å°Žå‰¤
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
PL1874917T3 (pl) 2005-04-26 2012-07-31 Teagasc The Agriculture And Food Dev Authority Kompozycja probiotyczna odpowiednia dla zwierząt
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
JP2007084533A (ja) 2005-08-24 2007-04-05 Prima Meat Packers Ltd 免ē–«åæœē­”čŖæēƀēµ„ęˆē‰©åŠć³č©²ēµ„ęˆē‰©ć‚’ęœ‰åŠ¹ęˆåˆ†ćØć™ć‚‹é£Ÿå“
US7625704B2 (en) 2005-08-31 2009-12-01 Fred Hutchinson Cancer Research Center Methods and compositions for identifying bacteria associated with bacteria vaginosis
DE602006009834D1 (de) 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzĆ¼ndlicher augenerkrankung
WO2007035057A1 (en) 2005-09-23 2007-03-29 Gwangju Institute Of Science And Technology Composition for preventing or treating artritis comprising lactic acid bacteria and collangen as active ingredients
EP1931364B1 (en) 2005-10-06 2010-07-21 Nestec S.A. Probiotic enterococci for improved immunity
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
PT1940243E (pt) 2005-10-24 2011-10-17 Nestec Sa FormulaĆ§Ć£o de fibras alimentares e mĆ©todo de administraĆ§Ć£o
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc ę©Ÿčƒ½ę€§é£Ÿå“
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
JP2009520689A (ja) 2005-12-01 2009-05-28 ć‚·ć‚§ćƒ¼ćƒŖćƒ³ć‚° ć‚³ćƒ¼ćƒćƒ¬ć‚¤ć‚·ćƒ§ćƒ³ ē‚Žē—‡éšœå®³ćŠć‚ˆć³å¾®ē”Ÿē‰©ę€§ē–¾ę‚£ć‚’処ē½®ć™ć‚‹ćŸć‚ć®åŒ–合ē‰©
WO2007098371A2 (en) 2006-02-16 2007-08-30 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
US20080260906A1 (en) 2006-03-17 2008-10-23 Marko Stojanovic Compositions comprising probiotic and sweetener components
JP5031249B2 (ja) 2006-03-22 2012-09-19 å­¦ę ”ę³•äŗŗ北里ē ”ē©¶ę‰€ ē‚Žē—‡ęŠ‘制作ē”Øć®ć‚ć‚‹čŒä½“å«ęœ‰ēµ„ęˆē‰©
ES2688934T3 (es) 2006-03-29 2018-11-07 Nestec S.A. Suplementos alimentarios que contienen probiĆ³ticos
US20090252708A1 (en) 2006-05-18 2009-10-08 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
AU2007267560B2 (en) 2006-05-26 2010-10-21 Nestec S.A. Methods of use and nutritional compositions of Touchi Extract
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2008015374A2 (en) 2006-08-04 2008-02-07 Shs International Ltd Protein free formula
WO2008031438A2 (en) 2006-09-13 2008-03-20 Region Hovedstaden V/Gentofte Hospital Treatment of asthma, eczema and/or allergy using non-pathogenic organisms
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
CA2667167C (en) 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
US20080118473A1 (en) 2006-11-01 2008-05-22 The Procter & Gamble Company Methods of treating a respiratory condition comprising probiotic treatment
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworĆ³w
WO2008064489A1 (en) 2006-12-01 2008-06-05 Mcmaster University Probiotics to inhibit inflammation
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung fĆ¼r die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (en) 2006-12-29 2008-07-10 Washington University In St. Louis Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject
JP2008195635A (ja) 2007-02-09 2008-08-28 Crossfield Bio Inc 馬ē”Øä¹³é…øčŒč£½å‰¤
GB0703285D0 (en) * 2007-02-20 2007-03-28 Cutler Daniel Retractable covering apparatus
US9408818B2 (en) 2007-02-28 2016-08-09 Mead Johnson Nutrition Company Method for the utilization of and product containing inactivated probiotic
US8557233B2 (en) 2007-03-28 2013-10-15 Alimentary Heath Limited Probiotic bifidobacterium strains
NZ580006A (en) 2007-03-28 2012-03-30 Alimentary Health Ltd Probiotic bifidobacterium strain 41387
US20080299098A1 (en) 2007-04-24 2008-12-04 Chea-Yun Se Broad-Spectrum Antibacterial and Antifungal Activity of Lactobacillus Johnsonii D115
EP1997499A1 (en) 2007-05-31 2008-12-03 Puleva Biotech, S.A. Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis
EP1997906A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Lactobacillus
EP1997907A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Bifidobacteria
EP1997905A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Nucleic acid amplification
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
ES2523575T3 (es) 2007-06-27 2014-11-27 Laboratorios Ordesa, S.L. Una nueva cepa de bifidobacterium y peptidos acitvos contra infecciones por rotavirus
US20110027348A1 (en) 2007-08-27 2011-02-03 Janos Feher Composition and method inhibiting inflammation
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009043856A2 (en) 2007-10-01 2009-04-09 University College Cork, National University Of Ireland, Cork Modulation of tissue fatty acid composition of a host by human gut bacteria
EP2203551B1 (en) 2007-10-20 2013-08-21 UniversitĆ© de LiĆØge Bifidobacterial species
ES2473625T3 (es) 2007-10-26 2014-07-07 Brenda E. Moore ComposiciĆ³n probiļæ½tica y mĆ©todos para inducir y mantener la pĆ©rdida de peso
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
EP2065048A1 (en) 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
BRPI0821165B8 (pt) 2007-12-07 2021-05-25 Nutricia Nv uso de uma composiĆ§Ć£o
US20100330190A1 (en) 2007-12-17 2010-12-30 Compans Richard W Immunogenic compositions and methods of use thereof
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
RU2010132283A (ru) 2008-02-06 2012-03-20 Š”Š·Šµ ŠŸŃ€Š¾ŠŗтŠµŃ€ Š­Š½Š“ Š“эŠ¼Š±Š» ŠšŠ¾Š¼ŠæŠ°Š½Šø (US) ŠšŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø, сŠæŠ¾ŃŠ¾Š±Ń‹ Šø Š½Š°Š±Š¾Ń€Ń‹ Š“Š»Ń ŠæŠ¾Š²Ń‹ŃˆŠµŠ½Šøя ŠøŠ¼Š¼ŃƒŠ½Š½Š¾Š³Š¾ Š¾Ń‚Š²ŠµŃ‚Š° Š½Š° рŠµŃŠæŠøрŠ°Ń‚Š¾Ń€Š½Š¾Šµ Š·Š°Š±Š¾Š»ŠµŠ²Š°Š½ŠøŠµ
EP2103226A1 (en) 2008-03-18 2009-09-23 Friesland Brands B.V. Long-life probiotic food product
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
US8741365B2 (en) 2008-05-13 2014-06-03 Glycotope Gmbh Fermentation process
MX2008006546A (es) 2008-05-21 2009-11-23 Sigma Alimentos Sa De Cv Bifidobacteria productora de Ć”cido fĆ³lico, composiciĆ³n alimenticia y uso de la bifidobacteria.
CN101590081A (zh) 2008-05-28 2009-12-02 青岛äøœęµ·čÆäøšęœ‰é™å…¬åø å‡øč…¹ēœŸę†čŒå’Œäø¤å½¢ēœŸę†čŒåˆ¶å‰‚及其åŗ”ē”Ø
CN102940652B (zh) 2008-05-28 2015-03-25 青岛äøœęµ·čÆäøšęœ‰é™å…¬åø äø¤å½¢ēœŸę†čŒåˆ¶å‰‚及其åŗ”ē”Ø
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
EP2133088A3 (en) 2008-06-09 2010-01-27 Nestec S.A. Rooibos and inflammation
WO2009151315A1 (en) 2008-06-13 2009-12-17 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
WO2009154463A2 (en) 2008-06-20 2009-12-23 Stichting Top Institute Food And Nutrition Butyrate as a medicament to improve visceral perception in humans
EP2138186A1 (en) 2008-06-24 2009-12-30 Nestec S.A. Probiotics, secretory IgA and inflammation
WO2010002241A1 (en) 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
KR101017448B1 (ko) 2008-09-18 2011-02-23 ģ£¼ģ‹ķšŒģ‚¬ķ•œźµ­ģ•¼ģæ ė„“ķŠø ėŒ€ģž„ģ˜ ź±“ź°• ģ¦ģ§„ ķšØėŠ„ģ„ ź°–ėŠ” ė¹„ķ”¼ė„ė°•ķ…Œė¦¬ģ›€ ė”±ź²€ ģ—ģ“ģ·Øģ™€ģ“8004 ė° ģ“ė„¼ ģœ ķšØģ„±ė¶„ģœ¼ė”œ ķ•Øģœ ķ•˜ėŠ” ģ œķ’ˆ
US8137718B2 (en) 2008-09-19 2012-03-20 Mead Johnson Nutrition Company Probiotic infant products
US20100074870A1 (en) 2008-09-19 2010-03-25 Bristol-Myers Squibb Company Probiotic infant products
KR101057357B1 (ko) 2008-09-22 2011-08-17 ź“‘ģ£¼ź³¼ķ•™źø°ģˆ ģ› ģœ ģ‚°ź·  ė° ģ½œė¼ź²ģ„ ģœ ķšØģ„±ė¶„ģœ¼ė”œ ķ¬ķ•Øķ•˜ėŠ” ź“€ģ ˆģ—¼ ģ˜ˆė°© ė˜ėŠ” ģ¹˜ė£Œģš© ģ•½ģ œķ•™ģ  ģ”°ģ„±ė¬¼ ė° ģ‹ķ’ˆ ģ”°ģ„±ė¬¼
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
CN102231957A (zh) 2008-12-05 2011-11-02 雀巢äŗ§å“ęŠ€ęœÆę“åŠ©ęœ‰é™å…¬åø ē”ØäŗŽä½Žå‡ŗē”Ÿä½“重婓å„æēš„ē»„合ē‰©
CN102325458B (zh) 2008-12-19 2014-02-26 雀巢äŗ§å“ęŠ€ęœÆę“åŠ©ęœ‰é™å…¬åø é¢„é˜²åŠę²»ē–—č½®ēŠ¶ē—…ęÆ’č…¹ę³»
IT1392672B1 (it) 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
JP5710876B2 (ja) 2009-03-26 2015-04-30 ć‚Æćƒ­ć‚¹ćƒ•ć‚£ćƒ¼ćƒ«ćƒ‰ćƒć‚¤ć‚Ŗę Ŗ式会ē¤¾ ę–°č¦ćƒ“ćƒ•ć‚£ćƒ‰ćƒć‚Æ惆ćƒŖć‚¦ćƒ å±žå¾®ē”Ÿē‰©ćŠć‚ˆć³ćć®åˆ©ē”Ø
US20120142605A1 (en) * 2009-05-05 2012-06-07 Amgen Inc. Methods of treating psoriasis
WO2010129839A1 (en) 2009-05-07 2010-11-11 Tate & Lyle Ingredients France SAS Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
US8784798B2 (en) 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
EP2251022A1 (en) 2009-05-11 2010-11-17 Nestec S.A. Non-replicating micro-organisms and their immune boosting effect
EP2251020A1 (en) 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
KR20100128168A (ko) 2009-05-27 2010-12-07 ģ¤‘ģ•™ėŒ€ķ•™źµ ģ‚°ķ•™ķ˜‘ė „ė‹Ø ź³µģ•” ė¦¬ė†€ė ˆģ‚° ģƒģ‚°ėŠ„ģ“ ģš°ģˆ˜ķ•œ ģ‹ ź·œķ•œ ź· ģ£¼
US20100311686A1 (en) 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2010143940A1 (en) 2009-06-12 2010-12-16 N.V. Nutricia Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages
EP2443259A4 (en) 2009-06-16 2012-10-10 Univ Columbia BIOMARKERS FOR AUTISM AND USES THEREOF
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
CA2768301A1 (en) 2009-07-24 2011-01-27 Southwest Regional Pcr, Llc Universal microbial diagnosis, detection, quantification, and specimen-targeted therapy
MY163002A (en) 2009-08-18 2017-07-31 Nestec Sa A nutritional composition comprising bifidobacterium longum strains and reducing food allergy symptoms, especially in infants and children
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
ES2660008T3 (es) 2009-09-23 2018-03-20 Thomas Julius Borody Terapia para infecciones entĆ©ricas crĆ³nicas
EP2308498A1 (en) 2009-09-30 2011-04-13 Nestec S.A. Administration of Bifidobacterium breve during infancy to prevent inflammation later in life
CA2776420A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
WO2011044208A1 (en) 2009-10-06 2011-04-14 Scott Dorfner Antibiotic formulations providing reduced gastrointentestinal side effects
PL2498789T3 (pl) 2009-11-11 2017-01-31 Alimentary Health Limited Probiotyczny szczep bifidobacterium
CA2780649C (en) 2009-12-18 2014-09-30 Hill's Pet Nutrition, Inc. Pet food compositions including probiotics and methods of manufacture and use thereof
US20150104418A1 (en) 2014-12-18 2015-04-16 Microbios, Inc. Bacterial composition
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
NL2004200C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
JP5737646B2 (ja) 2010-03-24 2015-06-17 ę£®äø‹ä»äø¹ę Ŗ式会ē¤¾ ęŠ—ć‚¢ćƒ¬ćƒ«ć‚®ćƒ¼å‰¤
WO2011121379A1 (en) 2010-03-30 2011-10-06 Assistance Publique - Hopitaux De Paris Use of bifidobacteria for preventing allergy in breastfed infants
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011149335A1 (en) 2010-05-25 2011-12-01 N.V. Nutricia Immune imprinting nutritional composition
CN102947441A (zh) 2010-06-01 2013-02-27 ē©†å°”ē ”ē©¶ä¼äøšęœ‰é™č“£ä»»å…¬åø ę„č‡Ŗę‹Ÿę†čŒå±žēš„ē»†čƒžē»„åˆ†ć€å…¶ē»„合ē‰©å’Œä½æē”Øę‹Ÿę†čŒęˆ–å…¶ē»†čƒžē»„分ēš„ę²»ē–—ę–¹ę³•
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国ē«‹å¤§å­¦ę³•äŗŗę±äŗ¬å¤§å­¦ åˆ¶å¾”ę€§ļ½”ē“°čƒžć®å¢—ę®–ć¾ćŸćÆ集ē©ć‚’čŖ˜å°Žć™ć‚‹ä½œē”Ø悒꜉恙悋ēµ„ęˆē‰©
TWI417054B (zh) 2010-06-15 2013-12-01 Jen Shine Biotechnology Co Ltd ꖰē©Žē³žč…øēƒčŒļ½Œļ½Šļ½“ļ¼ļ¼ļ¼‘及其ē›Šē”Ÿē”Ø途
EP2397145A1 (en) 2010-06-18 2011-12-21 Nestec S.A. L. johnsonii La1, B. longum NCC2705 and immune disorders
FR2962045B1 (fr) 2010-07-05 2012-08-17 Bifinove Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
TWI401086B (zh) 2010-07-20 2013-07-11 Univ China Medical čƒščŠ½ä¹³é…øę”æčŒåŠå…¶ē”Ø途
PL2598165T3 (pl) 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
KR101250463B1 (ko) 2010-10-12 2013-04-15 ėŒ€ķ•œėƼźµ­ ģ‹ ģƒģ•„ ė¶„ė³€ģ—ģ„œ ė¶„ė¦¬ķ•œ ė‚“ģ‚°ģ†Œģ„± ė¹„ķ”¼ė„ė°•ķ…Œė¦¬ģ›€ ė”±ź²€ ė¹„ķ”¼ė”ģŠ¤ ģœ ģ‚°ź·  ė° ģ“ė„¼ ģ“ģš©ķ•œ ķ”„ė”œė°”ģ“ģ˜¤ķ‹± ģ”°ģ„±ė¬¼
CA2815259A1 (en) 2010-10-27 2012-05-03 Quantibact A/S Capture of target dna and rna by probes comprising intercalator molecules
CN102031235B (zh) 2010-11-09 2012-07-25 äø­å›½å†œäøšå¤§å­¦ äø€ē§ē²Ŗ肠ēƒčŒanse228及其åŗ”ē”Ø
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
WO2012071380A1 (en) 2010-11-24 2012-05-31 Oragenics, Inc. Use of bacteria to treat and prevent respiratory infections
CN102093967B (zh) 2010-12-02 2013-01-30 äø­å›½å†œäøšē§‘学院ē‰¹äŗ§ē ”ē©¶ę‰€ äø€ę Ŗę°“č²‚ęŗå±Žč‚ ēƒčŒåŠå…¶åŗ”ē”Ø
ES2389547B1 (es) 2010-12-07 2013-08-08 Consejo Superior De Investigaciones CientĆ­ficas (Csic) Bifidobacterium cect 7765 y su uso en la prevenciĆ³n y/o tratamiento del sobrepeso, la obesidad y patologĆ­as asociadas.
EP2663367A4 (en) 2011-01-10 2014-08-06 Cleveland Biolabs Inc USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
DK2481299T3 (en) 2011-01-31 2017-02-06 Dr Fischer Gesundheitsprodukte Gmbh BIFIDOBACTERIUM BIFIDUM STREAMS FOR USE IN GASTROINTESTINAL DISEASES
JP5840368B2 (ja) 2011-02-02 2016-01-06 ć‚«ćƒ«ćƒ”ć‚¹ę Ŗ式会ē¤¾ 関ēƀē‚Žäŗˆé˜²ę”¹å–„ē”Øē‰©č³Ŗ
CN103491969A (zh) 2011-02-09 2014-01-01 ꋉē»“ę²ƒå…¬åø ę¢å¤å’Œé‡å»ŗč‚ é“å¾®ē”Ÿē‰©ē¾¤ēš„合ē”Ÿē“ ē»„合ē‰©
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composiĆ§Ć£o, mĆ©todos para substituir ou suplementar ou modificar uma microbiota do cĆ³lon de um sujeito, e para tratar um sujeito, e, uso de uma composiĆ§Ć£o
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Eduardo Nowill Alexandre agente imunomodulador e suas combinaƇƕes, seu uso e mƉtodo imunoterƁpico para a recontextualizaƇƧo, reprogramaƇƧo e reconduƇƧo do sistema imune em tempo real
WO2012140636A1 (en) 2011-04-11 2012-10-18 Alimentary Health Limited A probiotic formulation
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
CA2833633A1 (en) 2011-04-20 2012-10-26 Jason Fisher Composition and method for enhancing an immune response
JP6129821B2 (ja) 2011-05-13 2017-05-17 悰ćƒŖć‚³ć‚·ćƒ³ ćƒŖ惟惆惃惉 ćƒ©ć‚¤ć‚¢ćƒ“ćƒŖćƒ†ć‚£ćƒ¼ ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ ćƒ—ćƒ¬ćƒć‚¤ć‚Ŗćƒ†ć‚£ć‚Æć‚¹ćØ恗恦恮态ē²¾č£½ć•ć‚ŒćŸļ¼’ā€™āˆ’ćƒ•ć‚³ć‚·ćƒ«ćƒ©ć‚Æćƒˆćƒ¼ć‚¹ć€ļ¼“āˆ’ćƒ•ć‚³ć‚·ćƒ«ćƒ©ć‚Æćƒˆćƒ¼ć‚¹ć€ćŠć‚ˆć³ćƒ©ć‚Æ惈ć‚øćƒ•ć‚³ćƒ†ćƒˆćƒ©ć‚Ŗćƒ¼ć‚¹ć®ä½æē”Ø
CA2837081C (en) * 2011-05-23 2019-06-25 Washington State University Research Foundation Use of photosynthetic pigment stabilizing agents to regulate ripening and quality in fruits and vegetables
KR20120133133A (ko) 2011-05-30 2012-12-10 ķ•œźµ­ ķ•œģ˜ķ•™ ģ—°źµ¬ģ› ģƒģ•½ ģ¶”ģ¶œė¬¼ ė˜ėŠ” ģ“ģ˜ ģœ ģ‚°ź·  ė°œķšØė¬¼ģ„ ķ¬ķ•Øķ•˜ėŠ” ķ˜øķ”źø° ģ§ˆķ™˜ģ˜ ģ˜ˆė°© ė˜ėŠ” ģ¹˜ė£Œģš© ģ”°ģ„±ė¬¼
WO2012170478A2 (en) 2011-06-06 2012-12-13 The University Of North Carolina At Chapel Hill Methods and kits for detecting adenomas, colorectal cancer, and uses thereof
GB201110095D0 (en) 2011-06-15 2011-07-27 Danisco Method of treatment
JP2013005759A (ja) 2011-06-24 2013-01-10 Kyodo Milk Industry Co Ltd ćƒžć‚¦ć‚¹č…øå†…čŒå¢ć®ęŽØęø¬ę–¹ę³•
US20140128585A1 (en) 2011-07-07 2014-05-08 Nagaoka Perfumery Co., Ltd. Fructose absorption inhibitor
WO2013008102A2 (en) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
CN102304483A (zh) 2011-08-12 2012-01-04 北äŗ¬é‡‘ę³°å¾—ē”Ÿē‰©ē§‘ęŠ€č‚”ä»½ęœ‰é™å…¬åø äø€ę Ŗ鄲ē”Øå±Žč‚ ēƒčŒåŠå…¶åŗ”ē”Ø
KR101261872B1 (ko) 2011-08-23 2013-05-14 ėŒ€ķ•œėƼźµ­ (ģ‹ķ’ˆģ˜ģ•½ķ’ˆģ•ˆģ „ģ²˜ģž„) ģž„ė‚“ ėÆøģƒė¬¼ ķšØģ†Œė³µķ•©ģ²“ ė° ģ“ģ˜ ģ œģ”°ė°©ė²•
EP2756071B1 (en) * 2011-09-14 2017-12-20 University Of Guelph Media supplements and methods to culture human gastrointestinal anaerobic microorganisms
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
DK2750682T3 (en) 2011-10-11 2016-08-22 Achim Biotherapeutics Ab A composition comprising anaerobically cultured human intestinal flora
CN103082292B (zh) 2011-11-02 2015-03-04 ę·±åœ³åŽå¤§åŸŗ因ē ”ē©¶é™¢ ē½—ę–Æ갏菌(Roseburia)åœØę²»ē–—å’Œé¢„é˜²č‚„胖ē›ø关ē–¾ē—…äø­ēš„åŗ”ē”Ø
CN102373172B (zh) 2011-11-03 2013-03-20 北äŗ¬é¾™ē§‘ę–¹čˆŸē”Ÿē‰©å·„ēØ‹ęŠ€ęœÆęœ‰é™å…¬åø äø€ę Ŗå±Žč‚ ēƒčŒåŠå…¶åŗ”ē”Ø
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido lĆ”ctica probiĆ³tica
ITBG20120010A1 (it) 2012-02-24 2013-08-25 Milano Politecnico Dispositivo per l'addestramento chirurgico
ITMI20120471A1 (it) 2012-03-26 2013-09-27 Giovanni Mogna Composizione a base di ceppi di batteri bifidobacterium longum in grado di aiutare il prolungamento della vita
JP5792105B2 (ja) 2012-03-27 2015-10-07 ę£®ę°øä¹³ę„­ę Ŗ式会ē¤¾ 惩ć‚Æ惈āˆ’ļ½Žāˆ’ćƒ“ć‚Ŗćƒ¼ć‚¹ļ½‰ć®č£½é€ ę–¹ę³•
JP6201982B2 (ja) 2012-03-30 2017-09-27 å‘³ć®ē“ ę Ŗ式会ē¤¾ ē³–å°æē—…čŖ˜čµ·ē“°čŒ
US20130280724A1 (en) 2012-04-11 2013-10-24 Nestec Sa Methods for diagnosing impending diarrhea
MX2014012362A (es) 2012-04-13 2015-05-07 Trustees Boston College ComposiciĆ³n prebiĆ³tica y mĆ©todos de uso.
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
US10130665B2 (en) 2012-05-18 2018-11-20 Genome Research Limited Method for identifying bacteria for bacteriotherapy
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones CientĆ­ficas (Csic) Bacteroides cect 7771 y su uso en la prevenciĆ³n y tratamiento de sobrepeso, obesidad y alteraciones metabĆ³licas e inmunolĆ³gicas.
EP3659598A1 (en) 2012-06-04 2020-06-03 Gaurav Agrawal Compositions and methods for treating crohn's disease and related conditions and infections
CN102743420A (zh) 2012-06-06 2012-10-24 äøŠęµ·äŗ¤é€šå¤§å­¦ ę”¹å–„č‚ é“čŒē¾¤ē»“ęž„ēš„ę–¹ę³•åŠåŗ”ē”Ø
WO2014001368A1 (en) 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
CN104582506B (zh) 2012-07-31 2016-10-19 雀巢äŗ§å“ęŠ€ęœÆę“åŠ©ęœ‰é™å…¬åø ē”ØäŗŽäæƒčæ›ę‚£ęœ‰ē‚Žē—‡ę€§č‚ ē—…(ibd)ēš„ę‚£č€…ēš„č‚Œč‚‰éŖØéŖ¼å„åŗ·ēš„萄养ē»„合ē‰©
WO2014019271A1 (en) 2012-08-01 2014-02-06 Bgi Shenzhen Biomarkers for diabetes and usages thereof
BR112015004165A2 (pt) 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc mĆ©todos e composiƧƵes laxantes para o tratamento de constipaĆ§Ć£o e condiƧƵes e doenƧas gastrointestinais relacionadas
CN114949001A (zh) 2012-08-29 2022-08-30 加州ē†å·„学院 å­¤ē‹¬ē—‡č°±ē³»éšœē¢ēš„čÆŠę–­å’Œę²»ē–—
WO2014043593A2 (en) 2012-09-13 2014-03-20 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
KR101473058B1 (ko) 2012-09-19 2014-12-16 ģ£¼ģ‹ķšŒģ‚¬ ģŽŒė°”ģ“ģ˜¤ķ… ź³¼ėƼģ„± ėŒ€ģž„ ģ¦ķ›„źµ° ģ˜ˆė°© ė˜ėŠ” ģ¹˜ė£Œģš© ģ”°ģ„±ė¬¼
CN103652322B (zh) 2012-09-21 2016-02-10 äø“ę²‚ę€ē§‘ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§å«ä¹³é…ø菌ēš„复合ē›Šē”ŸčŒé„²ę–™ę·»åŠ å‰‚ēš„åˆ¶å¤‡ę–¹ę³•
EP3401396A1 (en) 2012-10-03 2018-11-14 Metabogen AB Treating or preventing atherosclerosis or associated diseases by beta-carotene
FR2997091B1 (fr) 2012-10-22 2016-05-06 Fond Mediterranee Infection Utilisation d'un compose antioxydant pour la culture de bacteries sensibles a la tension en oxygene
WO2014067976A1 (en) 2012-10-30 2014-05-08 Nestec S.A. Compositions comprising microparticles and probiotics to deliver a synergistic immune effect
WO2014070225A1 (en) 2012-10-30 2014-05-08 Deerland Enzymes, Inc. Prebiotic compositions comprising one or more types of bacteriophage
WO2014070014A1 (en) 2012-11-01 2014-05-08 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
WO2014075745A1 (en) 2012-11-19 2014-05-22 UniversitƩ Catholique de Louvain Use of akkermansia for treating metabolic disorders
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
CN104918624A (zh) 2012-11-26 2015-09-16 ę‰˜é©¬ę–ÆĀ·ęœ±åˆ©å¶ę–ÆĀ·ę³¢ę“›čæŖ ę¢å¤ęŽ’ę³„ē‰©å¾®ē”Ÿē‰©ē¾¤ēš„ē»„合ē‰©åŠå…¶åˆ¶é€ å’Œä½æē”Øę–¹ę³•
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College ManipulaĆ§Ć£o e otimizaĆ§Ć£o de sistemas, mĆ©todos e composiƧƵes para manipulaĆ§Ć£o de sequĆŖncias com domĆ­nios funcionais
CN105209621B (zh) 2012-12-12 2021-05-25 åøƒē½—å¾·ē ”ē©¶ę‰€ęœ‰é™å…¬åø åƹē”ØäŗŽåŗåˆ—ę“ēŗµēš„ę”¹čæ›ēš„ē³»ē»Ÿć€ę–¹ę³•å’Œé…¶ē»„合ē‰©čæ›č”Œēš„å·„ē؋化和优化
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
US20140193464A1 (en) 2013-01-08 2014-07-10 Imagilin Technology, Llc Effects of probiotics on humans and animals under environmental or biological changes
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
EP2958575B1 (en) 2013-02-22 2019-04-03 The Regents of The University of California Composition comprising lactobaccilus johnsonii 456 and its use in treating or preventing diseases
KR20150134356A (ko) 2013-03-05 2015-12-01 ė¦¬ģ—‘ģŠ¤ģœ ė‹ˆė²„ģ‹œķ…Œģ“ķŠø ź·øė”œė‹ź² ģ—¼ģ¦ģ„ ģ–µģ œķ•˜źø° ģœ„ķ•œ ķŽ˜ģ¹¼ė¦¬ ė°•ķ…Œė¦¬ģ›€ ķ”„ė¼ģš°ģŠ¤ė‹ˆģ¹˜ģ“ htf-f (dsm 26943)ģ˜ ģš©ė„
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US9669059B2 (en) 2013-03-15 2017-06-06 University Of Florida Research Foundation, Incorporated Butyrogenic bacteria as probiotics to treat clostridium difficile
JP2016519664A (ja) 2013-03-15 2016-07-07 ć‚»ćƒ¬ć‚¹ ć‚»ćƒ©ćƒ”ćƒ„ćƒ¼ćƒ†ć‚£ć‚Æć‚¹ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ 惍惃惈ćƒÆćƒ¼ć‚Æ悒åŸŗć«ć—ćŸå¾®ē”Ÿē‰©ēµ„ęˆē‰©åŠć³ę–¹ę³•
CN103142656A (zh) 2013-03-18 2013-06-12 å¹æ州ēŸ„光ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø č„†å¼±ę‹Ÿę†čŒåœØåˆ¶å¤‡é˜²ę²»ē»“č‚ ē™Œē»„合ē‰©äø­ēš„åŗ”ē”Ø
CN103156888A (zh) 2013-03-18 2013-06-19 å¹æ州ēŸ„光ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø č„†å¼±ę‹Ÿę†čŒåœØåˆ¶å¤‡ę²»ē–—ē‚Žē—‡ę€§č‚ ē—…ē»„合ē‰©äø­ēš„åŗ”ē”Ø
CN103146620A (zh) 2013-03-25 2013-06-12 å¹æ州ēŸ„光ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø å…·ęœ‰ē›Šē”ŸčŒē‰¹ę€§ēš„č„†å¼±ę‹Ÿę†čŒ
JP2014196260A (ja) 2013-03-29 2014-10-16 公ē«‹å¤§å­¦ę³•äŗŗ儈č‰ÆēœŒē«‹åŒ»ē§‘大学 ę…¢ę€§é–‰å”žę€§č‚ŗē–¾ę‚£ć®äŗˆé˜²åˆćÆę²»ē™‚ē”Øēµ„ęˆē‰©
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2014182966A1 (en) 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
KR102099503B1 (ko) 2013-06-05 2020-04-09 ė¦¬ė°”ģ“ģ˜¤ķ‹±ģŠ¤, ģøģ½”ķ¼ė ˆģ“ķ‹°ė“œ ėÆøģƒė¬¼ģƒ ė³µģ› ģš”ė²•(mrt) ģ”°ģ„±ė¬¼
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
WO2014201037A2 (en) 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
WO2014200334A1 (en) 2013-06-14 2014-12-18 N.V. Nutricia Synbiotic composition for treatment of infections in allergic patients
WO2015003001A1 (en) 2013-07-01 2015-01-08 The Washington University Methods for identifying supplements that increase gut colonization by an isolated bacterial species, and compositions derived therefrom
JP6643984B2 (ja) 2013-07-02 2020-02-12 ć‚Ŗćƒ¼ć‚¹ćƒˆćƒŖć‚¢ćƒŽćƒ“ć‚” ć‚·ćƒ³ć‚¬ćƒćƒ¼ćƒ« ćƒ—ćƒ©ć‚¤ćƒ™ćƒ¼ćƒˆ ćƒŖ惟惆惃惉 ć‚«ćƒ—ć‚»ćƒ«åŒ–ē“°čƒžć‚’凍ēµä¹¾ē‡„ć™ć‚‹ę–¹ę³•ć€å‡ēµä¹¾ē‡„ć•ć‚ŒćŸć‚«ćƒ—ć‚»ćƒ«åŒ–ē“°čƒžć€å‡ēµä¹¾ē‡„ć•ć‚ŒćŸć‚«ćƒ—ć‚»ćƒ«åŒ–ē“°čƒžć‚’å«ć‚€ēµ„ęˆē‰©ć€ćŖć‚‰ć³ć«ć€ćć®ć‚ˆć†ćŖē“°čƒžćŠć‚ˆć³ēµ„ęˆē‰©ć®ä½æē”Ø
WO2015003305A1 (zh) 2013-07-08 2015-01-15 吉ē‘žé«˜ę–°ē§‘ęŠ€č‚”ä»½ęœ‰é™å…¬åø ē”µå­ēƒŸē›’
US9764019B2 (en) 2013-07-09 2017-09-19 Vedanta Biosciences, Inc. Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US20160192689A1 (en) 2013-07-31 2016-07-07 Wikifoods, Inc. Encapsulated functional food compositions
EP3033091B1 (en) 2013-08-16 2022-09-07 Versitech Limited Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma
CN103509741B (zh) 2013-08-22 2015-02-18 ę²³åŒ—å†œäøšå¤§å­¦ åøƒåŠ³ē‰¹čŒauh-jld56及其åœØē‰›č’”č‹·å…ƒč½¬åŒ–äø­ēš„åŗ”ē”Ø
US10203329B2 (en) 2013-09-12 2019-02-12 The Johns Hopkins University Biofilm formation to define risk for colon cancer
EP3071052B1 (en) 2013-10-18 2020-02-26 InnovaChildfood AB A nutritionally balanced composite meal for infants and small children and a method of producing said meal
PL229020B1 (pl) 2013-11-13 2018-05-30 Inst Biotechnologii Surowic I Szczepionek Biomed Spolka Akcyjna Nowy szczep Bifidobacterium breve
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CN103981115B (zh) 2013-12-24 2018-10-26 北äŗ¬å¤§ä¼Ÿå˜‰ē”Ÿē‰©ęŠ€ęœÆč‚”ä»½ęœ‰é™å…¬åø äø€ę Ŗé«˜ęŠ—é€†ę€§å±Žč‚ ēƒčŒåŠå…¶åŗ”ē”Ø
CN103981117B (zh) 2013-12-24 2018-10-26 北äŗ¬å¤§ä¼Ÿå˜‰ē”Ÿē‰©ęŠ€ęœÆč‚”ä»½ęœ‰é™å…¬åø äø€ę Ŗé«˜ęŠ—é€†ę€§å±Žč‚ ēƒčŒåŠå…¶åŸ¹å…»ę–¹ę³•å’Œåŗ”ē”Ø
CN103820363B (zh) 2014-01-27 2016-02-24 ē¦å»ŗēœå†œäøšē§‘学院ē”Ÿē‰©ęŠ€ęœÆē ”ē©¶ę‰€ äø€ē§å±Žč‚ ēƒčŒčŒē²‰ēš„制备äøŽåŗ”ē”Ø
CN103865846B (zh) 2014-02-27 2016-03-30 ę‰¬å·žē»æäæē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§å±Žč‚ ēƒčŒåŠå…¶åˆ¶å¤‡ę–¹ę³•
CN103849590B (zh) 2014-03-25 2016-07-06 äøŠęµ·äŗ¤é€šå¤§å­¦ äø€ę Ŗ耐é…øēŸ­åŒę­§ę†čŒBB8dpH及其åŗ”ē”Ø
KR101683474B1 (ko) 2014-03-26 2016-12-08 ģ£¼ģ‹ķšŒģ‚¬ ģŽŒė°”ģ“ģ˜¤ķ… ź³¼ėƼģ„± ėŒ€ģž„ ģ¦ķ›„źµ° ģ˜ˆė°© ė˜ėŠ” ģ¹˜ė£Œģš© ģ”°ģ„±ė¬¼
US9783858B2 (en) 2014-04-02 2017-10-10 Northwestern University Altered microbiome of chronic pelvic pain
US20150374760A1 (en) 2014-04-09 2015-12-31 Jose U. Scher Methods for treating psoriasis and psoriatic arthritis
KR101583546B1 (ko) 2014-04-09 2016-01-11 źµ­ė¦½ģ•”ģ„¼ķ„° ģœ ģ „ģž ė‹¤ķ˜•ģ„±ģ„ ģ“ģš©ķ•œ ģ†Œė¼ķŽ˜ė‹™ ģ¹˜ė£Œģ— ėŒ€ķ•œ ė°˜ģ‘ģ„± ģ˜ˆģø”ė°©ė²•
WO2015156419A1 (en) 2014-04-10 2015-10-15 Riken Compositions and methods for induction of th17 cells
CN104195075B (zh) 2014-08-14 2017-04-19 ē”Ÿåˆē”Ÿē‰©ē§‘ęŠ€č‚”ä»½ęœ‰é™å…¬åø äø€ē§å±Žč‚ ēƒčŒef08及包含它ēš„é„²ę–™ę·»åŠ ē‰©å’Œé„²ę–™
WO2015168534A1 (en) 2014-05-02 2015-11-05 Novogy, Inc. Therapeutic treatment of gastrointestinal microbial imbalances through competitive microbe displacement
JP6629840B2 (ja) 2014-05-08 2020-01-15 ćƒ‘ćƒŽćƒ—ćƒ†ć‚¹ćƒ»ćƒ•ć‚”ćƒ¼ćƒžćƒ»ć‚²ćƒ¼ć‚Øćƒ ćƒ™ćƒ¼ćƒćƒ¼ ēœ¼ć®ē–¾ę‚£ćŠć‚ˆć³éšœå®³ć‚’処ē½®ć™ć‚‹ćŸć‚ć®åŒ–合ē‰©
CN106687130B (zh) 2014-08-05 2020-01-21 ę·±åœ³åŽå¤§åŸŗ因ē§‘ęŠ€ęœ‰é™å…¬åø ēœŸę†čŒå±žåœØé¢„é˜²å’Œę²»ē–—ē»“ē›“肠ē™Œē›ø关ē–¾ē—…äø­ēš„ē”Ø途
US10925953B2 (en) 2014-08-28 2021-02-23 Yale University Compositions and methods for treating an inflammatory disease or disorder
WO2016036615A1 (en) 2014-09-03 2016-03-10 California Institute Of Technology Microbe-based modulation of serotonin biosynthesis
CN104546934B (zh) * 2014-09-30 2019-04-09 ę·±åœ³åŽå¤§åŸŗ因ē§‘ęŠ€ęœ‰é™å…¬åø ē²Ŗå‰ÆꋟꝆ菌åœØę²»ē–—ęˆ–é¢„é˜²ē±»é£Žę¹æę€§å…³čŠ‚ē‚Žęˆ–å…¶ē›ø关ē–¾ē—…äø­ēš„åŗ”ē”Ø
CN104546933A (zh) 2014-09-30 2015-04-29 ę·±åœ³åŽå¤§åŸŗ因ē§‘ęŠ€ęœ‰é™å…¬åø ē²ŖꋟꝆ菌åœØę²»ē–—ęˆ–é¢„é˜²ē±»é£Žę¹æę€§å…³čŠ‚ē‚Žęˆ–å…¶ē›ø关ē–¾ē—…äø­ēš„åŗ”ē”Ø
CN104546932A (zh) 2014-09-30 2015-04-29 ę·±åœ³åŽå¤§åŸŗ因ē§‘ęŠ€ęœ‰é™å…¬åø åµå½¢ę‹Ÿę†čŒåœØę²»ē–—ęˆ–é¢„é˜²ē±»é£Žę¹æę€§å…³čŠ‚ē‚Žęˆ–å…¶ē›ø关ē–¾ē—…äø­ēš„åŗ”ē”Ø
CN104546940A (zh) 2014-09-30 2015-04-29 ę·±åœ³åŽå¤§åŸŗ因ē§‘ęŠ€ęœ‰é™å…¬åø å¹³åøøꋟꝆ菌åœØę²»ē–—ęˆ–é¢„é˜²ē±»é£Žę¹æę€§å…³čŠ‚ē‚Žęˆ–å…¶ē›ø关ē–¾ē—…äø­ēš„åŗ”ē”Ø
CN104546935A (zh) 2014-09-30 2015-04-29 ę·±åœ³åŽå¤§åŸŗ因ē§‘ęŠ€ęœ‰é™å…¬åø å¤šå½¢ę‹Ÿę†čŒåœØę²»ē–—ęˆ–é¢„é˜²ē±»é£Žę¹æę€§å…³čŠ‚ē‚Žęˆ–å…¶ē›ø关ē–¾ē—…äø­ēš„åŗ”ē”Ø
CN104546942A (zh) 2014-09-30 2015-04-29 ę·±åœ³åŽå¤§åŸŗ因ē§‘ęŠ€ęœ‰é™å…¬åø å¤šę°ę‹Ÿę†čŒåœØę²»ē–—ęˆ–é¢„é˜²ē±»é£Žę¹æę€§å…³čŠ‚ē‚Žęˆ–å…¶ē›ø关ē–¾ē—…äø­ēš„åŗ”ē”Ø
WO2016057671A1 (en) 2014-10-07 2016-04-14 University Of Virginia Patent Foundation Compositions and methods for preventing and treating infection
CN107249611A (zh) 2014-10-24 2017-10-13 čæ›åŒ–ē”Ÿē‰©ē³»ē»Ÿč‚”ä»½ęœ‰é™å…¬åø ę“»åŒ–ēš„åŒę­§ę†čŒåŠå…¶åŗ”ē”Øę–¹ę³•
KR20170086492A (ko) 2014-10-30 2017-07-26 ģŗ˜ė¦¬ķ¬ė‹ˆģ•„ ģøģŠ¤ķ‹°ķŠœķŠø ģ˜¤ėøŒ ķ…Œķ¬ė†€ė”œģ§€ ģ‹ ź²½ė°œė‹¬ ģž„ģ• ģ—ģ„œģ˜ ķ–‰ė™ģ„ ź°œģ„ ģ‹œķ‚¤źø° ģœ„ķ•œ ė°•ķ…Œė¦¬ģ•„ė„¼ ķ¬ķ•Øķ•˜ėŠ” ģ”°ģ„±ė¬¼ ė° ė°©ė²•
US10124025B2 (en) 2014-10-30 2018-11-13 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
CN104435000A (zh) 2014-11-12 2015-03-25 ę±Ÿå—å¤§å­¦ ä¹³é…ø菌åƹę”Æ갔ē®”å“®å–˜ę²»ē–—äø­ēš„åŗ”ē”Ø
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prƩbiotiques, et leurs procƩdƩs d'utilisation pour la modulation du microbiome
ES3010296T3 (en) 2014-11-25 2025-04-02 Memorial Sloan Kettering Cancer Center Intestinal microbiota and gvhd
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
CN104560820B (zh) 2014-12-30 2017-10-20 ę­å·žåøˆčŒƒå¤§å­¦ å±Žč‚ ēƒčŒkq2.6及åŗ”ē”Ø
SG10201907660YA (en) 2015-01-23 2019-10-30 Univ Temple Use of short chain fatty acids in cancer prevention
CN105982919A (zh) 2015-02-26 2016-10-05 ēŽ‹ę±‰ęˆ ē”Ÿē‰©å‡é€Ÿå‰‚ꊗē™ŒęŠ€ęœÆ
WO2016139217A1 (en) 2015-03-04 2016-09-09 Ab-Biotics, S.A. Composition comprising anaerobically cultivated human intestinal microbiota
EP3270938A4 (en) 2015-03-18 2018-12-19 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
WO2016149449A1 (en) 2015-03-18 2016-09-22 Tufts University Compositions and methods for preventing colorectal cancer
HK1253064A1 (zh) 2015-06-01 2019-06-06 The University Of Chicago 通čæ‡ę“ēŗµå…±ē”Ÿå¾®ē”Ÿē‰©čŒē¾¤åƹē™Œē—‡ēš„ę²»ē–—
EP3662917A1 (en) 2015-06-15 2020-06-10 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactƩriennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactƩriennes
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
CN105112333A (zh) 2015-08-31 2015-12-02 ę±Ÿå—å¤§å­¦ äø€ē§å…·ęœ‰č‰Æå„½č‚ é“å®šę®–čƒ½åŠ›ēš„é•æåŒę­§ę†čŒåŠē­›é€‰ę–¹ę³•å’Œåŗ”ē”Ø
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactƩriennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3379935A4 (en) 2015-11-25 2019-08-28 Memorial Sloan-Kettering Cancer Center METHOD AND COMPOSITIONS FOR REDUCING VANCOMYCIN RESISTANT ENTEROKOKKEN
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
AU2017234120B2 (en) 2016-03-14 2024-06-20 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
TWI802545B (zh) 2016-07-13 2023-05-21 č‹±å•†ļ¼”ļ¼¤č£½č—„ęœ‰é™å…¬åø 包含ē“°čŒčŒę Ŗ之ēµ„合ē‰©
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018112365A2 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
US20190314427A1 (en) 2016-12-16 2019-10-17 Evelo Biosciences, Inc. Methods of treating cancer using parabacteroides
BR112019013125B1 (pt) 2016-12-23 2022-02-08 Keio University ComposiƧƵes farmacĆŖuticas compreendendo uma mistura bacteriana purificada

Also Published As

Publication number Publication date
PL3369425T3 (pl) 2021-06-28
US11433106B2 (en) 2022-09-06
RS60245B1 (sr) 2020-06-30
SG10201912321RA (en) 2020-02-27
HUE052737T2 (hu) 2021-05-28
CO2017013231A2 (es) 2018-03-28
EP3204025B1 (en) 2019-09-11
EP3369425B1 (en) 2021-01-27
PT3549592T (pt) 2020-05-18
ZA201707774B (en) 2018-11-28
AU2016278069B2 (en) 2020-07-09
SMT201900665T1 (it) 2020-01-14
RS61538B1 (sr) 2021-04-29
PL3204025T3 (pl) 2020-02-28
JP2018502551A (ja) 2018-02-01
SG10201912322PA (en) 2020-02-27
EP3549592A1 (en) 2019-10-09
SI3549592T1 (sl) 2020-10-30
MD3369425T2 (ro) 2021-07-31
MD3549592T2 (ro) 2020-07-31
US20230310517A1 (en) 2023-10-05
RS59558B1 (sr) 2019-12-31
SMT202000227T1 (it) 2020-05-08
SI3369425T1 (sl) 2021-03-31
CY1124013T1 (el) 2022-05-27
ME03584B (me) 2020-07-20
ES2787523T3 (es) 2020-10-16
CN108738311A (zh) 2018-11-02
US20170354695A1 (en) 2017-12-14
JP2018199695A (ja) 2018-12-20
CA3182899A1 (en) 2016-12-22
TWI782682B (zh) 2022-11-01
EA201890049A1 (ru) 2018-06-29
US10493112B2 (en) 2019-12-03
TW202200173A (zh) 2022-01-01
HRP20210246T1 (hr) 2021-05-28
CL2017003191A1 (es) 2018-06-22
JP6389950B2 (ja) 2018-09-12
PL3549592T3 (pl) 2020-11-16
EP3369425A1 (en) 2018-09-05
EP3549592B1 (en) 2020-02-12
US20180344780A1 (en) 2018-12-06
HRP20200702T1 (hr) 2020-07-24
HUE048823T2 (hu) 2020-08-28
LT3369425T (lt) 2021-04-12
PT3369425T (pt) 2021-03-08
CN112370468A (zh) 2021-02-19
MA41060B1 (fr) 2019-11-29
EP3884953A1 (en) 2021-09-29
PE20180266A1 (es) 2018-02-06
SMT202100204T1 (it) 2021-05-07
CY1122467T1 (el) 2021-01-27
MD3204025T2 (ro) 2020-02-29
US20200138874A1 (en) 2020-05-07
DK3204025T3 (da) 2019-11-25
DK3549592T3 (da) 2020-04-20
TWI739746B (zh) 2021-09-21
CA2988686A1 (en) 2016-12-22
AU2020241605A1 (en) 2020-10-29
HUE046221T2 (hu) 2020-02-28
IL255783B2 (en) 2023-06-01
CN108738311B (zh) 2020-11-03
MX2017016564A (es) 2018-02-21
SI3204025T1 (sl) 2020-02-28
KR20180012845A (ko) 2018-02-06
ME03784B (me) 2021-04-20
BR112017025003A2 (pt) 2018-08-07
ES2863913T3 (es) 2021-10-13
DK3369425T3 (da) 2021-03-01
CY1123196T1 (el) 2021-10-29
CA2988686C (en) 2023-01-24
HRP20192057T1 (hr) 2020-02-21
TW201709918A (zh) 2017-03-16
WO2016203220A1 (en) 2016-12-22
EP3204025A1 (en) 2017-08-16
LT3204025T (lt) 2019-12-10
LT3549592T (lt) 2020-05-25
PT3204025T (pt) 2019-12-16
AU2016278069A1 (en) 2017-12-14
IL255783A (en) 2018-01-31
MA41060A (fr) 2017-08-15

Similar Documents

Publication Publication Date Title
ES2863913T3 (es) Composiciones que comprenden cepas bacterianas
ES2753779T3 (es) Blautia stercosis y wexlerae para la utilizaciĆ³n en el tratamiento de enfermedades inflamatorias y autoinmunes
ES2748812T3 (es) Composiciones que comprenden cepas bacterianas
ES2748826T3 (es) Composiciones que comprenden cepas bacterianas
ES2914430T3 (es) Composiciones que comprenden cepas bacterianas
ES2818991T3 (es) Composiciones que comprenden cepas bacterianas
ES2766867T3 (es) Composiciones que comprenden cepas bacterianas
ES2705157T3 (es) Composiciones que comprenden cepas bacterianas
HK1260125B (en) Compositions comprising bacterial strains
HK1240835B (en) Compositions comprising bacterial strains
HK1240835A1 (en) Compositions comprising bacterial strains
HK1244202B (en) Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
HK1240831B (en) Compositions comprising bacterial strains
HK1240831A1 (en) Compositions comprising bacterial strains
HK1246675B (en) Compositions comprising bacterial strains